CLINUVEL Kommuniqué III
Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 23 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 14 June 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Jeffries Healthcare Conference June 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...
Read More
H.C. Wainwright Global Investment Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Notice of change of interests of initial substantial holder
Melbourne, Australia, 25 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notice of initial substantial holder
Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Strategic Update IV
CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL progresses vitiligo treatment program
A new potential therapy for the pigment loss disorder vitiligo will undergo...
Read More
CLINUVEL progresses vitiligo study
CLINUVEL today announced that it will start treatment of vitiligo patients with...
Read More
Notification regarding unquoted securities
Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read More